MBX Biosciences ratios data for the quarter ended Jun 2026. These financial ratios cover 8 quarters of results from Sep 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|
| Efficiency | ||||||||
| Assets AverageAssets Avg. | 275.47M | 257.23M | 238.72M | 315.80M | 392.61M | 418.92M | 444.31M | |
| Valuation | ||||||||
| Price to EarningsP/E | -9.33 | -12.58 | -10.33 | -19.75 | -27.68 | -52.19 | -60.38 | -71.35 |
| Price to BookP/B | 0.62 | 0.76 | 1.05 | 1.75 | 1.54 | 3.12 | 3.24 | 6.46 |
| Enterprise Value | -107.79M | -66.00M | 5.89M | 158.38M | 206.80M | 777.70M | 980.00M | 2,228.25M |
| EV to EBIT | 5.50 | 3.55 | -0.22 | -7.26 | -8.64 | -30.15 | -35.94 | -54.44 |
| EV to EBITDA | 5.50 | 3.55 | -0.22 | -7.26 | -8.64 | -30.15 | -35.94 | -54.44 |
| Market Capitalization | 169.28M | 196.15M | 246.67M | 383.29M | 598.48M | 1,151.40M | 1,419.98M | 2,646.83M |
| Price to FCFP/FCF | -11.50 | -12.16 | -10.64 | -21.69 | -27.28 | -60.30 | -68.78 | -112.52 |
| EV to FCF | 7.32 | 4.09 | -0.25 | -8.96 | -9.43 | -40.73 | -47.47 | -94.73 |
| EV to CFO | 7.35 | 4.12 | -0.26 | -9.08 | -9.60 | -42.49 | -48.50 | -98.50 |
| Return Ratios | ||||||||
| Return on Capital Employed [ROCE]ROCE | -25.79% | -32.99% | -38.14% | -29.92% | -26.00% | -24.43% | -28.03% | |
| Return on Assets [ROA]ROA | -22.48% | -28.56% | -32.26% | -25.49% | -22.15% | -20.67% | -23.47% |